NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $34.50 Average Target Price from Analysts

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have been given an average recommendation of “Hold” by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $34.50.

NRXP has been the subject of a number of recent research reports. Zacks Research cut shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 26th. UBS Group reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 26th. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Tuesday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. Finally, Wall Street Zen cut shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bleakley Financial Group LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter valued at $318,000. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals during the 2nd quarter worth about $54,000. Two Sigma Investments LP raised its position in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of NRx Pharmaceuticals by 27.9% in the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after buying an additional 37,598 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Stock Performance

NRx Pharmaceuticals stock opened at $3.40 on Wednesday. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The stock has a market capitalization of $147.22 million, a P/E ratio of -6.18 and a beta of 2.19. The stock has a fifty day moving average of $3.63 and a 200-day moving average of $3.17.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings results on Monday, August 17th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million. On average, research analysts forecast that NRx Pharmaceuticals will post -0.36 earnings per share for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.